PCSK9 and endothelial dysfunction: These studies collectively illustrate the multifaceted role of PCSK9: the former reveals its independent regulatory effect on platelet reactivity in healthy individuals, while the latter demonstrates that its inhibitor reduces markers of platelet activation and endothelial dysfunction in ACS patients and diminishes interactions between PCSK9, platelets, and endothelial cells.